1. Pink Sheet
  2. >>Geography
  3. >>Europe

Industry Roundup: Cardinal Buys Harvard Drug, Similac Lawsuit, State AGs Question Supplement Oversight

Cardinal acquires Harvard Drug; Similac ‘organic’ claims deceptive – complaint; N.Y., Ind. criticize supplement regulatory flexibility; Amway headquarters manufacturing site opens; and more news in brief.

Cardinal Health Inc.broadens its OTC drug portfolio by acquiring Harvard Drug Group, a distributor of Rx and nonprescription generics and related products to retail, institutional and alternate care customers, from Court Square Capital Partners for $1.115 billion in cash and new debt. Dublin, Ohio-based Cardinal said June 5 the acquisition also expands its telesales programs and capabilities; and brings specialized packaging offerings to meet the needs of hospital systems and other institutions. Harvard changed its name in 1997 from Great Lakes Wholesale to include all its divisions under one business name and since then acquired additional businesses – including drug compounding, Rx and veterinary drugs and home health care Also see "Harvard Drug Continues Expansion With Watson’s Rugby OTC Business" - Pink Sheet, 5 November, 2012.. Cardinal said Harvard Drug had revenues of around $450 million in 2014; 450 employees and two distribution facilities are included in the transaction.

A lawsuit seeking class action status claims [Abbott Nutrition] falsely labels Similac Advance Organic infant formula as organic because 26 ingredients are irradiated substances, synthetic compounds or ingredients produced from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ClinicalTrials.gov Or ISRCTN: Getting Transparency Right For UK Trials

 
• By Vibha Sharma

ISRCTN’s systems are being redesigned to facilitate compliance with upcoming requirements in the UK’s clinical trials legislation.

Spain Slashes Wait Between EU Drug Authorization And Financing Decisions

 
• By Francesca Bruce

Spanish authorities say that that timelines for drug reimbursement decisions can be improved further with the right submissions from companies.

Spain Beats England To Tevimbra Reimbursement Recommendations

 
• By Francesca Bruce

Spanish authorities have published more pricing and reimbursement reports as part of a new drive to increase transparency.

More from Geography

UroGen’s Bladder Cancer Drug Draws Split Decision From US FDA Panel

 
• By Sue Sutter

The Oncologic Drugs Advisory Committee voted 5-4 that the overall benefit-risk of UGN-102 is not favorable in patients with recurrent low grade, intermediate-risk, non-muscle invasive bladder cancer and also divided on whether randomized trials should be required for future development programs.

US FDA Will Help States Apply To Import Cheaper Drugs From Canada

 
• By Cathy Kelly

The FDA is not currently signaling that stringent rules for the process will be relaxed, but the agency's change in approach is notable.

Global Pandemic Deal Adopted As 124 Countries Say Yes; US Sits Out

 
• By Neena Brizmohun

Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.